Skip to main content
Top
Published in: PharmacoEconomics 1/2017

01-12-2017 | Review Article

The Identification, Review and Synthesis of Health State Utility Values from the Literature

Authors: Roberta Ara, John Brazier, Tessa Peasgood, Suzy Paisley

Published in: PharmacoEconomics | Special Issue 1/2017

Login to get access

Abstract

Systematic literature reviews of health-related quality of life (HRQoL) evidence that are to inform economic models can be challenging due to the volume of hits identified in searches using generic terms for HRQoL. Nevertheless, a robust review of the literature is required to ensure that the health state utility values (HSUVs) used in the economic model are the most appropriate available. This article provides a synopsis of literature relating to identifying, reviewing and synthesising HSUVs. The process begins with scoping the needs of the economic model, including the definitions of health states and the requirements of any reimbursement agencies. A sequence of searches may be required as the economic model evolves. The terminology used for HRQoL measures may be problematic, and as there is no robust HRQoL filter [equivalent to that applied for randomised control trial (RCTs)], sifting the results of sensitive searches can be resource intensive. Alternative approaches such as forward and backward citation searches may reduce the resources required, while maintaining the integrity of the search. Any included studies should be assessed in terms of quality using a recommended checklist, and insufficient detail in the primary studies should be noted as a short-coming in this exercise. Subject to homogeneity (similar populations, same measure and preference weights) evidence can be pooled in some way, although methodological research into the appropriateness of alternative techniques for meta-analysis is in its infancy. Reporting standards are key and as a minimum should include details on searches, inclusion/exclusion criteria (together with rationale for exclusion at each stage), assessment of quality and relevance of included studies, and justification for the choice of final HSUVs.
Literature
2.
go back to reference Peasgood T, Herrmann K, Kanis JA, Brazier JE. An updated systematic review of health state utility values for osteoporosis related conditions. Osteoporos Int. 2009;20(6):853.CrossRefPubMed Peasgood T, Herrmann K, Kanis JA, Brazier JE. An updated systematic review of health state utility values for osteoporosis related conditions. Osteoporos Int. 2009;20(6):853.CrossRefPubMed
3.
go back to reference Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess. 2007;11(7):1–231.CrossRef Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess. 2007;11(7):1–231.CrossRef
4.
go back to reference Papaioannou D, Brazier JE, Paisley S. NICE DSU Technical Support Document 9: the identification, review and synthesis of health state utility values from the literature. National Health Service, 2010. http://www.nicedsu.org.uk. Papaioannou D, Brazier JE, Paisley S. NICE DSU Technical Support Document 9: the identification, review and synthesis of health state utility values from the literature. National Health Service, 2010. http://​www.​nicedsu.​org.​uk.
5.
go back to reference Papaioannou D, Brazier J, Paisley S. Systematic searching and selection of health state utility values from the literature. Value Health. 2013;16(4):686–95.CrossRefPubMed Papaioannou D, Brazier J, Paisley S. Systematic searching and selection of health state utility values from the literature. Value Health. 2013;16(4):686–95.CrossRefPubMed
6.
go back to reference Rowen D, Azzabi Zouraq I, Chevrou-Severac H, van Hout B. International regulations and recommendations. Current issue Pharmacoeconomics. Rowen D, Azzabi Zouraq I, Chevrou-Severac H, van Hout B. International regulations and recommendations. Current issue Pharmacoeconomics.
8.
go back to reference Brazier J, Ara R, Rowen D, Chevrou-Severac H. A review of generic preference-based measures for use in cost-effectiveness models. PharmacoEconomics. 2017. doi:10.1007/s40273-017-0545-x. Brazier J, Ara R, Rowen D, Chevrou-Severac H. A review of generic preference-based measures for use in cost-effectiveness models. PharmacoEconomics. 2017. doi:10.​1007/​s40273-017-0545-x.
9.
go back to reference Rowen D, Brazier J, Ara R, Azzabi Zouraq I. The role of condition-specific preference-based measures in health technology assessment. PharmacoEconomics. 2017. doi:10.1007/s40273-017-0546-9. Rowen D, Brazier J, Ara R, Azzabi Zouraq I. The role of condition-specific preference-based measures in health technology assessment. PharmacoEconomics. 2017. doi:10.​1007/​s40273-017-0546-9.
12.
go back to reference Arber M, Garcia S, Veale T, Edwards M, Shaw A, Glanville J. Performance of search filters to identify health state utility studies. 2016. ISPOR 19th Annual European Congress. Vienna. Arber M, Garcia S, Veale T, Edwards M, Shaw A, Glanville J. Performance of search filters to identify health state utility studies. 2016. ISPOR 19th Annual European Congress. Vienna.
13.
go back to reference Paisley S, Booth A, Mensinkai S. Health-related quality of life studies. Etext on Health Technology Assessment (HTA) information resources. Bethesda, MD: US National Library of Medicine (NLM), National Information Center on Health Services Research and Healthcare Technology (NICHSR), 2005. Paisley S, Booth A, Mensinkai S. Health-related quality of life studies. Etext on Health Technology Assessment (HTA) information resources. Bethesda, MD: US National Library of Medicine (NLM), National Information Center on Health Services Research and Healthcare Technology (NICHSR), 2005.
14.
go back to reference Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, Lloyd A, Norman R. Estimating health-state utility for economic models in clinical studies: an ISPOR Good Research Practices Task Force Report. Value Health. 2016;19(6):704–19.CrossRefPubMed Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, Lloyd A, Norman R. Estimating health-state utility for economic models in clinical studies: an ISPOR Good Research Practices Task Force Report. Value Health. 2016;19(6):704–19.CrossRefPubMed
15.
go back to reference Doth AH, Hansson PT, Jensen MP, Taylor RS. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain. 2010;149(2):338–44.CrossRefPubMed Doth AH, Hansson PT, Jensen MP, Taylor RS. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain. 2010;149(2):338–44.CrossRefPubMed
16.
go back to reference Higgins J, Thompson S. Controlling the risk of spurious findings from meta-regression. Stat Med. 2004;23:1663–82.CrossRefPubMed Higgins J, Thompson S. Controlling the risk of spurious findings from meta-regression. Stat Med. 2004;23:1663–82.CrossRefPubMed
17.
go back to reference Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis. New York: Wiley; 2011. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis. New York: Wiley; 2011.
18.
go back to reference Peasgood T, Brazier J. Is meta-analysis for utility values appropriate given the potential impact different elicitation methods have on values? Pharmacoeconomics. 2015;33(11):1101–5.CrossRefPubMedPubMedCentral Peasgood T, Brazier J. Is meta-analysis for utility values appropriate given the potential impact different elicitation methods have on values? Pharmacoeconomics. 2015;33(11):1101–5.CrossRefPubMedPubMedCentral
Metadata
Title
The Identification, Review and Synthesis of Health State Utility Values from the Literature
Authors
Roberta Ara
John Brazier
Tessa Peasgood
Suzy Paisley
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue Special Issue 1/2017
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-017-0547-8

Other articles of this Special Issue 1/2017

PharmacoEconomics 1/2017 Go to the issue